Ovarian cyst haemorrhage as a complication of acute myelomonocytic leukaemia induction therapy.
AMML
anticoagulation
chemotherapy
ovarian cyst haemorrhage
thrombocytopenia
Journal
Clinical medicine (London, England)
ISSN: 1473-4893
Titre abrégé: Clin Med (Lond)
Pays: England
ID NLM: 101092853
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
entrez:
17
11
2019
pubmed:
17
11
2019
medline:
22
9
2020
Statut:
ppublish
Résumé
Here we present a case of acute ovarian cyst haemorrhage in a young female during induction therapy for acute myelomonocytic leukaemia (AMML). A patient undergoing chemotherapy on the AML19 trial for AMML developed severe abdominal pain and haemodynamic compromise during cycle 2 of fludarabine, cytarabine and idarubicin. The patient was found to have a large ruptured haemorrhagic ovarian cyst on computed tomography. She was managed conservatively due to relative haematological contraindications to surgery and haemodynamic stability following transfer to the high dependency unit. The patient had recently discontinued anticoagulation for pulmonary emboli due to thrombocytopenia. This highlights the importance of recognising coexistent pathology in patients undergoing high intensity chemotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Here we present a case of acute ovarian cyst haemorrhage in a young female during induction therapy for acute myelomonocytic leukaemia (AMML).
CASE PRESENTATION
METHODS
A patient undergoing chemotherapy on the AML19 trial for AMML developed severe abdominal pain and haemodynamic compromise during cycle 2 of fludarabine, cytarabine and idarubicin. The patient was found to have a large ruptured haemorrhagic ovarian cyst on computed tomography. She was managed conservatively due to relative haematological contraindications to surgery and haemodynamic stability following transfer to the high dependency unit. The patient had recently discontinued anticoagulation for pulmonary emboli due to thrombocytopenia.
CONCLUSIONS
CONCLUSIONS
This highlights the importance of recognising coexistent pathology in patients undergoing high intensity chemotherapy.
Identifiants
pubmed: 31732594
pii: 19/6/509
doi: 10.7861/clinmed.2019-0355
pmc: PMC6899253
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
509-510Informations de copyright
© 2019 Royal College of Physicians.
Références
Best Pract Res Clin Obstet Gynaecol. 2009 Oct;23(5):711-24
pubmed: 19299205